EUVIMEDEUVIMED entdecken
Crossref

Impact of Levothyroxine on Progression to and Complications of Cirrhosis in MASH

Abhinav K Rao, Don C Rockey

Digestive Diseases and Sciences · 2025-10 · 70 (10) · 3538-3545

DOI: 10.1007/s10620-025-09375-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, online erschienen am 30.08.2025. Verfasst von Abhinav K Rao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC, USA. Hauptthemen laut MEDLINE: Thyroxine, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease, Hypertension, Portal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Resmetirom, a liver-targeted thyroid hormone receptor-β (THR-β) agonist, used to treat MASH, shares a similar mechanism of action with levothyroxine, a nonselective (THR-α/β) receptor agonist used to treat hypothyroidism. Given the potential effect of levothyroxine on THR-β, we hypothesized that it may have beneficial effects in MASH patients. METHODS: We used TriNetX to examine patients aged ≥ 18 years with MASH treated with levothyroxine from 1/1/16 to 1/1/25. Patients prescribed levothyroxine (levothyroxine group) were compared to those not receiving them (control group). Patients with previous cirrhosis or liver transplant were excluded. To control for disease severity and underlying comorbidities, propensity score matching (PSM) was performed. RESULTS: Of 109,268 patients with MASH, 17,629 (16%) received levothyroxine. Following PSM, we examined 15,076 patients in each group. MASH patients with or without levothyroxine treatment were predominantly White females, with a mean [SD] bilirubin, INR, and creatinine of 0.6 [0.7], 1.1 [0.4], and 0.9 [1.2], respectively. Comorbidities, BMIs, and MASH therapies including GLP-1s, SGLT-2s, and statins were similar in both groups. Over a mean [SD] follow-up of 2.8 [1.8] years, patients receiving levothyroxine had a similar rate of progression to cirrhosis (HR: 1.08; 95% CI 0.97-1.21; p = 0.16) as patients not on levothyroxine. In patients who developed cirrhosis, those receiving levothyroxine had a small, but statistically significantly higher risk of developing any portal hypertensive complication (HR: 1.33; 95% CI 1.18-1.49; p < 0.001) than those not receiving levothyroxine. CONCLUSION: MASH patients prescribed levothyroxine had a similar rate of progression to cirrhosis and a slightly higher rate of portal hypertension complications than those not prescribed levothyroxine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThyroxineLiver CirrhosisNon-alcoholic Fatty Liver DiseaseHypertension, PortalHypothyroidismDisease ProgressionCase-Control StudiesPropensity ScoreFollow-Up StudiesRetrospective StudiesHumansMaleFemaleAdultMiddle AgedAgedTreatment Outcome

Stichwörter der Autor:innen

AscitesDecompensationHepatic encephalopathyHepatorenal syndromeSpontaneous bacterial peritonitisVariceal bleeding

Substanzen

Thyroxine

Autor:innen und Institutionen

  • Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC, USA.
  • Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC, USA. rockey@musc.edu.
  • Department of Gastroenterology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 908, MSC 702, Charleston, SC, 29425, USA. rockey@musc.edu.

Förderung

  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of General Medical Sciences

Zitieren

APA

Rao, A. K., & Rockey, D. C. (2025). Impact of Levothyroxine on Progression to and Complications of Cirrhosis in MASH. Digestive Diseases and Sciences, 70(10), 3538-3545. https://doi.org/10.1007/s10620-025-09375-3

Vancouver

Rao AK, Rockey DC. Impact of Levothyroxine on Progression to and Complications of Cirrhosis in MASH. Digestive Diseases and Sciences. 2025;70(10):3538-3545. doi:10.1007/s10620-025-09375-3

BibTeX
@article{Rao2025,
  author = {Rao, Abhinav K and Rockey, Don C},
  title = {Impact of Levothyroxine on Progression to and Complications of Cirrhosis in MASH},
  journal = {Digestive Diseases and Sciences},
  year = {2025},
  volume = {70},
  number = {10},
  pages = {3538--3545},
  doi = {10.1007/s10620-025-09375-3}
}
Kostenlos starten →